A post hoc analysis of linaclotide in pediatric patients with functional constipation and neurodevelopmental disorders

Read full text Summarise with VIRAT
Authors: Hannibal Person, Jeffrey S. Hyams, Rinarani M. Sanghavi, Valentina Shakhnovich, Katherine J. Kosch, Moming Li, Danielle D'Achino, Julie Khlevner, Bruno Pedro Chumpitazi, Miguel Saps
Cited by: 0
References: 39

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

OBJECTIVES: Functional constipation (FC) is common in children with comorbid neurodevelopmental disorders (NDD) and its optimal treatment may be challenged by adherence and medication tolerability issues in this population. We assessed the efficacy and safety of linaclotide in pediatric patients with FC and NDD. METHODS: This post hoc analysis of a Phase 3, randomized, placebo-controlled study assessed oral linaclotide 72 µg once daily for 12 weeks in patients aged 6-17 years with FC and NDD. The primary endpoint was change from baseline (CFB) in weekly spontaneous bowel movement (SBM) frequency. In efficacy comparisons, an absolute standardized mean difference (SMD) > 0.2 was considered indicative of a treatment difference. RESULTS: In this analysis of 57 pediatric patients (linaclotide n = 25; placebo n = 32), 91% had attention-deficit/hyperactivity disorder; other NDDs included autism spectrum disorder, tic disorders, and sensory processing disorders. CFB in weekly SBM frequency over 12 weeks was greater with linaclotide versus placebo (2.09 vs. 0.59, respectively; SMD 0.688). Linaclotide was also associated with greater improvements relative to placebo in stool consistency (CFB 1.37 vs. 0.55, respectively) and straining score (CFB -0.98 vs. -0.59). Most patients (≥96%) achieved ≥80% dosing compliance with once-daily administration of linaclotide or placebo. Linaclotide was well tolerated, with a safety profile consistent with that reported previously. CONCLUSIONS: In children with FC and comorbid NDD, linaclotide 72 µg once daily was associated with improved constipation outcomes, high adherence, and a well-tolerated safety profile, similar to that seen in the overall study population. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04026113 (https://clinicaltrials.gov/study/NCT04026113).

Fields of Study & Subjects

Gastrointestinal motility and disorders Congenital gastrointestinal and neural anomalies Pharmaceutical studies and practices

Publication details

Journal / source
Journal of Pediatric Gastroenterology and Nutrition
Volume
83
Issue
1
Pages
21–28
Publication date
30 March 2026
Language
EN